Very interesting new press release

No idea why the Intercept share price went down given that it’ll be much easier now to get a positive trial result with statistical significance on only one or other of the co-primary endpoints and it’s reduced the number of subjects required in total as well!

It certainly does raise the probability of success – I’m a Consultant Statistician as should know

The analysts at Leerink certainly don’t !